Low-molecular-mass secretome profiling identifies C-C motif chemokine 5 as a potential plasma biomarker and therapeutic target for nasopharyngeal carcinoma.
Cancer cell secretome profiling has been shown to be a promising strategy for identifying potential body fluid-accessible cancer biomarkers and therapeutic targets. However, very few reports have investigated low-molecular-mass (LMr) proteins (<15kDa) in the cancer cell secretome. In the present study, we applied tricine-SDS-gel-assisted fractionation in conjunction with LC-MS/MS to systemically identify LMr proteins in the secretomes of three nasopharyngeal carcinoma (NPC) cell lines. We examined two NPC tissue transcriptome datasets to identify LMr genes/proteins that are highly upregulated in NPC tissues and also secreted/released from NPC cells, obtaining 35 candidates. We verified the overexpression of four targets (LSM2, SUMO1, RPL22, and CCL5) in NPC tissues by immunohistochemistry and demonstrated elevated plasma levels of two targets (S100A2 and CCL5) in NPC patients by ELISA. Notably, plasma CCL5 showed good power (AUC 0.801) for discriminating NPC patients from healthy controls. Additionally, functional assays revealed that CCL5 promoted migration of NPC cells, an effect that was effectively blocked by CCL5-neutralizing antibodies and maraviroc, a CCL5 receptor antagonist. Collectively, our data indicate the feasibility of the tricine-SDS-gel/LC-MS/MS approach for efficient identification of LMr proteins from cancer cell secretomes, and suggest that CCL5 is a potential plasma biomarker and therapeutic target for NPC.


CONCLUSIONS
Both LMr proteome and cancer cell secretome represent attractive reservoirs for discovery of cancer biomarkers and therapeutic targets. Our present study provides evidence for the practicality of using the tricine-SDS-PAGE/LC-MS/MS approach for in-depth identification of LMr proteins from the NPC cell secretomes, leading to the discovery of CCL5 as a potential plasma biomarker and therapeutic target for NPC. We believe that the modified GeLC-MS/MS approach used here can be further applied to explore extremely low-abundance, extracellular LMr proteins with important biological functions in other cell lines and biospecimens.
Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
Shih-Jie
SJ
Lin
Kai-Ping
KP
Chang
Chia-Wei
CW
Hsu
Lang-Ming
LM
Chi
Kun-Yi
KY
Chien
Ying
Y
Liang
Ming-Hung
MH
Tsai
Yu-Tsun
YT
Lin
Jau-Song
JS
Yu
D014408:Biomarkers, Tumor / Q000097:blood*; D002277:Carcinoma; D045744:Cell Line, Tumor; D018946:Chemokine CCL5 / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000097:blood* / Q000473:pathology; D009363:Neoplasm Proteins / Q000097:blood*; D040901:Proteomics / Q000379:methods*
D014408:Biomarkers, Tumor; C483024:CCL5 protein, human; D018946:Chemokine CCL5; D009363:Neoplasm Proteins
10kDa heat shock protein, mitochondrial; 1D SDS-polyacrylamide gel electrophoresis in conjunction with nano-LC–MS/MS; 60S ribosomal protein L22; CCL5; Cancer biomarker; C–C motif chemokine 5; EBV; Epstein–Barr virus; GeLC–MS/MS; HSPE1; LMr; LSM2; LY6D; Low-molecular-mass protein; NPC; Nasopharyngeal carcinoma; RPL22; SNRPD1; SNRPF; SUB1; SUMO1; Secretome; TCEB1; TIMM13; Therapeutic target; U6 snRNA-associated Sm-like protein LSm2; activated RNA polymerase II transcriptional coactivator p15; low-molecular-mass; lymphocyte antigen 6D; mitochondrial import inner membrane translocase subunit Tim13.; nasopharyngeal carcinoma; small nuclear ribonucleoprotein F; small nuclear ribonucleoprotein Sm D1; small ubiquitin-related modifier 1; transcription elongation factor B polypeptide 1